Pericentric inversion of chromosome 10 involving the RET (ret proto-oncogene) gene at chromosome 10q11 is known to increase expression of the RET gene by fusion with KIF5B (10p11). Translocations with other fusion partners have also been described. Elevated expression of RET is observed in non-small cell lung cancer (NSCLC), in which the function of tyrosine kinase-based therapeutics is based on the inhibition of such fusion proteins. Translocations involving RET have also been described in thyroid carcinomas. The RET (10q11) Break probe is optimized to detect translocations involving the RET gene region at 10q11.
Chen et al, Cancer Genet Cytogenet, 2007, 178: 128-134.
Kohno et al, Nat Med, 2012, 18: 375-377.
Takeuchi et al, Nat Med, 2012, 18: 378-381.